4.6 Review

EMAST Type of Microsatellite Instability-A Distinct Entity or Blurred Overlap between Stable and MSI Tumors

期刊

GENES
卷 14, 期 7, 页码 -

出版社

MDPI
DOI: 10.3390/genes14071474

关键词

microsatellite instability; MSI; elevated microsatellite alterations at selected tetranucleotide repeats; EMAST; mismatch repair; MMR; MSH3; cancer; immunotherapy

向作者/读者索取更多资源

Microsatellite instability (MSI) is the accumulation of frameshifts in short tandem repeats, microsatellites, due to defective DNA mismatch repair (dMMR). Recently, another type of microsatellite instability called elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) has been reported across various tumors. The clinical significance of EMAST and its relation to MSI remains unclear.
Microsatellite instability (MSI) represents an accumulation of frameshifts in short tandem repeats, microsatellites, across the genome due to defective DNA mismatch repair (dMMR). MSI has been associated with distinct clinical, histological, and molecular features of tumors and has proven its prognostic and therapeutic value in different types of cancer. Recently, another type of microsatellite instability named elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) has been reported across many different tumors. EMAST tumors have been associated with chronic inflammation, higher tumor stage, and poor prognosis. Nevertheless, the clinical significance of EMAST and its relation to MSI remains unclear. It has been proposed that EMAST arises as a result of isolated MSH3 dysfunction or as a secondary event in MSI tumors. Even though previous studies have associated EMAST with MSI-low phenotype in tumors, recent studies show a certain degree of overlap between EMAST and MSI-high tumors. However, even in stable tumors, (MSS) frameshifts in microsatellites can be detected as a purely stochastic event, raising the question of whether EMAST truly represents a distinct type of microsatellite instability. Moreover, a significant fraction of patients with MSI tumors do not respond to immunotherapy and it can be speculated that in these tumors, EMAST might act as a modifying factor.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据